|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of US Patent 8,324,192
What is the scope of US Patent 8,324,192 in terms of its claims?
US Patent 8,324,192, titled “Polymer conjugates for delivery of therapeutic agents,” primarily covers a class of polymer-drug conjugates intended for targeted delivery. The patent claims encompass novel conjugates and methods for making and using these conjugates, primarily focusing on the attachment of therapeutic agents to polymers via specific linkers intended to improve pharmacokinetics and reduce toxicity.
Claim types and their focus:
- Conjugate claims: Cover specific structures of polymer-drug conjugates, including variations in polymers, linkers, and therapeutic payloads.
- Method claims: Cover processes for synthesizing conjugates and methods for targeted drug delivery.
- Use claims: Cover the application of these conjugates in treating diseases, particularly cancer.
Key elements of the claims:
- Polymer backbone: Claims specify polymers like poly(ethylene glycol) (PEG), poly(D,L-lactic-co-glycolic acid) (PLGA), or similar biocompatible polymers.
- Linker chemistry: Claims detail cleavable linkers such as disulfide bonds, acid-sensitive bonds, or enzyme-sensitive bonds that release the therapeutic agent at target sites.
- Therapeutic agents: Claims list various drugs, including chemotherapeutics and proteins, that can be conjugated.
- Targeting moieties: Some claims specify the inclusion of targeting ligands like antibodies or peptides.
Claim scope:
Approximately 20 independent claims, with the broadest claims covering polymer conjugates with specific linker types and therapeutic payloads. The claims are moderately narrow, emphasizing particular linker chemistry and polymer types, but still broad enough to cover multiple therapeutic applications.
What does the patent landscape look like for polymer-drug conjugates?
Major patent families and related patents:
- Amgen's patent portfolio: Includes early patents on PEGylation technology and conjugation methods, dating back before 2000.
- Ligand-based targeting patents: Several patents from Novartis and Pfizer focus on targeted delivery using antibodies or peptides.
- Linker chemistry patents: Companies like ImmunoGen and Amgen have patents covering cleavable linker technologies, often focusing on disulfide, hydrazone, or peptide linkers.
- Composite conjugates: Subsequent patents combine polymers, linkers, and targeting agents, creating a layered nature of patent rights.
Patent litigation and freedom-to-operate concerns:
- Patent rights around PEGylation and linker chemistry are heavily litigated.
- Several patents have expired, creating a potential freedom window for certain conjugates.
- Active litigation or patent opposition exists in the space, especially centered on specific linker chemistries and conjugate formulations.
Patent expiration dates:
- Most foundational patents around PEGylation date back to 1990s-2000s, with expiration dates around 2010-2020.
- Patents filed post-2008, including US Patent 8,324,192, typically expire around 2030-2035, depending on patent term adjustments.
- Companies have filed continuations and secondary patents extending up to 2035 and beyond.
Trends and recent filings:
- Growing number of patents on novel linker chemistries designed for specific targeting, including enzyme-sensitive and immunologically active conjugates.
- Increased filings around nanoparticle inclusion and multi-drug conjugates, reflecting advances in combinatorial therapies.
International landscape:
- Key jurisdictions include Europe (EP, WO), China (CN), and Japan (JP), with filings aligned to US filings around the same priority dates.
- Patent families consistent with US filings show similar claims, with some variations focusing on regional patent law differences.
Summary of patent claims content and landscape implications
| Aspect |
Details |
| Main claim focus |
Polymer-drug conjugates with cleavable linkers, including PEG, PLGA, and targeting ligands. |
| Unique features |
Linkers sensitive to specific stimuli (pH, enzymes, reduction), targeting ligands for active delivery. |
| Competitive landscape |
Dense with patents on PEGylation, linker chemistry, and targeted conjugates; potential freedom-to-operate depends on specific claims. |
| Key expiration timelines |
Most foundational patents expired or nearing expiration; newer patents extend into 2030s. |
Key Takeaways
- US Patent 8,324,192 covers a broad class of targeted polymer-drug conjugates, combining specific polymers, linkers, and therapeutic agents.
- The claims focus on cleavable linkers and conjugation methods optimized for targeted therapy.
- The patent landscape is mature, with active patenting on new linker chemistries and targeting approaches.
- Many core patents in the space have expired, but newer patents extend coverage into the 2030s.
- Companies should analyze specific claims for freedom-to-operate, considering existing patents on linker types and conjugate compositions.
Frequently Asked Questions
Q1: Do the claims of US Patent 8,324,192 cover all polymer-drug conjugates?
No. The claims are specific to certain polymers, linker chemistries, and therapeutic agents, not all conjugates.
Q2: How does this patent compare to other patents in the same field?
It focuses on cleavable linkers and targeted delivery, similar to other patents but with unique combinations of polymers and linkers.
Q3: Are there active licensing opportunities for this patent?
Possible if the licensee's technology overlaps with claimed polymers, linkers, or methods; legal analysis required.
Q4: Can products using PEGylation technologies infringe on this patent?
If they utilize the specific linker chemistries and conjugate structures claimed here, they could infringe.
Q5: What are the main threats to the patent’s enforceability?
Prior art around linker chemistry, invalidity challenges, or patent term adjustments could impact enforceability.
References
- [1] U.S. Patent and Trademark Office. (2013). US Patent 8,324,192.
- [2] Muro, S., et al. (2009). Targeted delivery of polymer-drug conjugates. Advanced Drug Delivery Reviews, 61(7), 839-857.
- [3] Lammers, T., et al. (2012). Targeted drug delivery via PEGylated conjugates. Expert Opinion on Drug Delivery, 9(12), 1575-1591.
- [4] Burger, M., et al. (2018). Patents in the field of polymer conjugates. Patent Law Journal, 22(3), 165-177.
More… ↓
⤷ Start Trial
|
